Safety Evaluation for New Drug Approval in Korea

被引:0
|
作者
Young-Ok Kim
Kwang-Won Ha
Kwang-Sik Choi
机构
[1] National Institute of Toxicological Research,General Toxicology Division
[2] Korea Food & Drug Administration,undefined
[3] Toxicology Department,undefined
关键词
Toxicity guidelines; Korea; New drug approval;
D O I
暂无
中图分类号
学科分类号
摘要
Current drug regulation in Korea is based on the Pharmaceutical Affairs Law, which has been revised 14 times. Toxicity guidelines are described in the Regulation for Evaluation on Safety and Efficacy of Drugs (Korea Food and Drug Administration Notification No. 1999–60, revised on December 22, 1999) and Guidelines for Toxicity Studies of Drugs (Korea Food and Drug Administration Notification No. 1999–61, revised on December 22, 1999). This paper describes the review process and toxicity guidelines for new drug approval in Korea.
引用
收藏
页码:285 / 291
页数:6
相关论文
共 50 条
  • [31] New Drug Approval for Weight Management
    不详
    NURSING FOR WOMENS HEALTH, 2024, 28 (01)
  • [32] Access and Safety-The FDA Drug Approval Conundrum
    Good, Chester B.
    Peasah, Samuel K.
    JAMA NETWORK OPEN, 2024, 7 (07)
  • [33] Canadian and US drug approval times and safety considerations
    Rawson, NSB
    Kaitin, KI
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (10) : 1403 - 1408
  • [34] The Complexity of Integrating Speed and Safety in Drug Development and Approval
    Charo, R. Alta
    JAMA INTERNAL MEDICINE, 2013, 173 (13) : 1165 - 1166
  • [35] New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and Risk Management (KIDS)
    Shin, Ju-Young
    Jung, Sun-Young
    Ahn, So-Hyeon
    Lee, Shin Haeng
    Kim, Su-Jin
    Seong, Jong-Mi
    Chung, Soo-Youn
    Park, Byung-Joo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (11) : 1115 - 1122
  • [36] Drug evaluation and approval process in the European Union
    San Miguel, MT
    Vargas, E
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (01): : 12 - 14
  • [37] NEW DRUG APPROVAL TIMES AND SAFETY WARNINGS IN THE UNITED STATES AND CANADA, 1992-2011
    Rawson, Nigel S. B.
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2013, 20 (02): : E67 - E81
  • [38] Early drug safety evaluation: Synergising new technologies
    Gautier, JC
    Boitier, E
    Leonard, JF
    Marchandeau, JP
    Roberts, R
    DRUG METABOLISM REVIEWS, 2003, 35 : 18 - 18
  • [39] Safety issues of new drugs following the approval
    Ludwig, W-D
    ONKOLOGIE, 2011, 34 : 218 - 219
  • [40] Preparing for safety issues following drug approval: pre-approval risk management considerations
    Dieck, Gretchen S.
    Sharrar, Robert G.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2013, 4 (05) : 220 - 228